Zobrazeno 1 - 10
of 346
pro vyhledávání: '"VT DeVita"'
Publikováno v:
Blood. 53:1014-1017
Five patients in the blastic phase of chronic granulocytic leukemia with massive splenomegaly were treated by intraarterial splenic artery infusion of cytosine arabinoside. All patients had massive splenomegaly associated with pain and/or hyperspleni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9279eaf683f2f88f0034b260ec4c9518
https://doi.org/10.1182/blood.v53.5.1014.1014
https://doi.org/10.1182/blood.v53.5.1014.1014
Publikováno v:
Blood. 47(6)
Thirty-two patients in the blastic phase of Philadelphia chromosome- positive chronic granulocytic leukemia (CGL) were studied in a prospective randomized trial in which vincristine--prednisone (19 patients) was compared with cytosine arabinoside--6-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::633f66c3bf6a58bfdbe2930f20d30d5e
https://pubmed.ncbi.nlm.nih.gov/1064434
https://pubmed.ncbi.nlm.nih.gov/1064434
Publikováno v:
Blood. 53(5)
Five patients in the blastic phase of chronic granulocytic leukemia with massive splenomegaly were treated by intraarterial splenic artery infusion of cytosine arabinoside. All patients had massive splenomegaly associated with pain and/or hyperspleni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5244e5b04b15e102d6979bc06fc505c
https://pubmed.ncbi.nlm.nih.gov/435637
https://pubmed.ncbi.nlm.nih.gov/435637
Publikováno v:
Blood. 47(2)
Enhanced tolerance to combination chemotherapy has been cited as an ancillary benefit of staging laparotomy and splenectomy in Hodgkin's disease. Seventeen patients with Hodgkin's disease and 15 with non- Hodgkin's lymphoma were subjected to nonthera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ff5b687e3b571214ee05b6fb233c356
https://pubmed.ncbi.nlm.nih.gov/1244920
https://pubmed.ncbi.nlm.nih.gov/1244920
Autor:
Longo DL; From the Yale Cancer Center, New Haven, CT (V.T.D.)., DeVita VT Jr; From the Yale Cancer Center, New Haven, CT (V.T.D.).
Publikováno v:
The New England journal of medicine [N Engl J Med] 2018 Jan 25; Vol. 378 (4), pp. 392-394. Date of Electronic Publication: 2017 Dec 10.
Autor:
DeVita VT Jr; Yale Cancer Center, Yale Univeristy School of Medicine, New Haven, Connecticut. vincent.devita@yale.edu., DeVita-Raeburn E; New York, New York., Moxley JH 3rd; Los Angeles, California.
Publikováno v:
Cancer research [Cancer Res] 2016 Mar 15; Vol. 76 (6), pp. 1303-4.
Autor:
DeVita VT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT - USA., Canellos GP; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA - USA.
Publikováno v:
Tumori [Tumori] 2016 Mar-Apr; Vol. 102 (2), pp. 124-6. Date of Electronic Publication: 2016 Mar 22.
Autor:
DeVita VT
Publikováno v:
Oncology (Williston Park, N.Y.) [Oncology (Williston Park)] 2016 Mar; Vol. 30 (3), pp. 210.
Autor:
Surbone A; Department of Medicine, New York University School of Medicine, New York, New York., DeVita VT Jr; Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, Connecticut.
Publikováno v:
Cancer [Cancer] 2016 Jan 15; Vol. 122 (2), pp. 176-7. Date of Electronic Publication: 2015 Oct 20.
Autor:
DeVita VT Jr; Yale Comprehensive Cancer Center, FMP 117, 333 Cedar Street, New Haven, CT 06519, USA., Eggermont AM; Cancer Institute, Gustave Roussy Cancer Campus, Grand Paris, 114 rue Édouard Vaillant, 94805 Villejuif, France., Hellman S; Department of Radiation and Cellular Oncology, The Ludwig Center for Metastasis Research, The University of Chicago Medical Center, 5758 South Maryland Avenue, Chicago, IL 60637, USA., Kerr DJ; Radcliffe Department of Medicine, University of Oxford, Headley Way, Oxford OX3 9DU, UK.
Publikováno v:
Nature reviews. Clinical oncology [Nat Rev Clin Oncol] 2014 Nov; Vol. 11 (11), pp. 663-9. Date of Electronic Publication: 2014 Sep 23.